Therapeutic | Frunevetmab |
Target | NGFB |
Heavy Chain | QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA |
Light Chain | DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Feline Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Unknown |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | PETization Technology |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Nexvet |
Conditions Approved | na |
Conditions Active | Feline osteoarthritis |
Conditions Discontinued | na |
Notes |